A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2006
11/02/2006	US20060246072 Methods of facilitating cell survival using neurotrophin mimetics
11/02/2006	US20060246064 monoclonal antibodies; treat bone diseases characterized by changes in bone resorption, such as osteoporosis, hypercalcemia, bone loss due to arthritis metastasis, immobilization or periodontal disease, Paget's disease; denosumab
11/02/2006	US20060246061 Method for generating monoclonal antibodies
11/02/2006	US20060246050 Catheter Composition and Uses Thereof
11/02/2006	US20060246046 Modified tridegins, production and use thereof as transglutaminase inihibitors
11/02/2006	US20060246045 Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concertration
11/02/2006	US20060246039 Growth differentiation factor-7
11/02/2006	US20060246037 Neuroprotective effects of atf6
11/02/2006	US20060246036 Delivery of therapeutics to the brain and spinal cord
11/02/2006	US20060246035 Methods and products related to treatment and prevention of hepatitis c virus infection
11/02/2006	US20060246028 Di-glycosil glyceryl compounds for the stabilisation and preservation of biomaterials
11/02/2006	US20060246012 Delivery of physiologically active compounds through an inhalation route
11/02/2006	US20060246011 Delivery of diphenhydramine through an inhalation route
11/02/2006	US20060246009 Novel Crystalline Forms of Tiotropium Bromide
11/02/2006	US20060246007 Use of osmolytes obtained from extremophilic bacteria the production of inhalable medicaments for the prophylaxis and treatment of pulmonary and cardiovascular diseases and an inhalation device comprising an osmolyte as active agent component
11/02/2006	US20060243667 Filtrate composition with a radiation absorber
11/02/2006	EP1717315A2 Osteoprotegerin binding proteins and receptors
11/02/2006	EP1717310A1 Lineage-directed induction of human mesenchymal stem cell differentiation
11/02/2006	EP1717249A1 Peptides containing a cholesterol recognition sequence and their uses
11/02/2006	EP1717244A1 Akt activity specifically inhibiting polypeptide
11/02/2006	EP1717238A1 Fungicidal heterocyclic compounds
11/02/2006	EP1717237A1 Anthranilamides, process for the production thereof, and pest controllers containing the same
11/02/2006	EP1717235A2 Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
11/02/2006	EP1717234A1 Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
11/02/2006	EP1717233A1 Histamine H3-receptor ligands and their therapeutic application
11/02/2006	EP1717230A1 Fused-ring 4-oxopyrimidine derivative
11/02/2006	EP1717229A1 Novel cyclic compound having 4-pyridylalkylthio group having (un)substituted amino introduced therein
11/02/2006	EP1717227A1 Substituted indole compounds, their preparation and use in medicaments
11/02/2006	EP1717226A1 2,7-substituted 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octan amide derivatives as renin inhibitors for the treatment of hypertension
11/02/2006	EP1717225A1 Bicyclic amide derivatives
11/02/2006	EP1717224A1 Peptidyl arginine deiminase type iv inhibitor
11/02/2006	EP1717220A2 Vanilloid receptor ligands and their use in treatments
11/02/2006	EP1716868A1 Anti-inflammatory analgesic for external use
11/02/2006	EP1716867A1 Preventives for migraine
11/02/2006	EP1716861A2 Inhibitors of proteasomal activity for stimulating bone and hair growth
11/02/2006	EP1716857A1 Composition for nkt cell activation
11/02/2006	EP1716856A2 The treatment of acne
11/02/2006	EP1716855A1 Remedy for external use for skin and mucosal injuries caused by viral infection
11/02/2006	EP1716854A1 External preparation for treating painful skin wound
11/02/2006	EP1716853A2 Treatment of cancers of the human body using ET743
11/02/2006	EP1716852A1 A composition comprising campothecin or a campothecin derivative and an alkylating agent for the treatment of cancer
11/02/2006	EP1716851A1 Thioamides and salts thereof and cytokine production inhibitors containing both
11/02/2006	EP1716848A1 Solid pharmaceutical composition containing a crystalline derivative of piperidine substituted in the 1,4 position
11/02/2006	EP1716846A2 Preparation and use of hydrogels
11/02/2006	EP1716845A1 Formulation of 5-aminolevulinic acid for dermal application
11/02/2006	EP1716766A1 Aiding of cognitive function
11/02/2006	EP1716756A1 Dietary supplement or functional food comprising an oil combination
11/02/2006	EP1716416A1 Modulators of angiogenesis and tumorigenesis
11/02/2006	EP1716236A2 Antisense oligonucleotides for treating unwanted pigmentation of the skin and hair
11/02/2006	EP1716235A2 Inhibitors of tgf-r signaling for treatment of cns disorders
11/02/2006	EP1716234A1 Substituted, non-coding nucleic acid molecule used for the therapeutic and prophylactic immune stimulation in humans and higher animals
11/02/2006	EP1716166A2 17-methylene- or 17-spiro-cyclopropane 7-substituted estra-1,3,5(10)-triene derivatives with anti-estrogenic activity
11/02/2006	EP1716162A1 Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases
11/02/2006	EP1716160A2 Novel inhibitors of chymase
11/02/2006	EP1716158A2 Silinane compounds as cysteine protease inhibitors
11/02/2006	EP1716156A2 Chemokine ccr5 receptor modulators
11/02/2006	EP1716155A1 Substituted thieno¬2,3-d\|pyrimidines as inhibitors of tie2
11/02/2006	EP1716153A2 Methods, compositions, and apparatuses for forming macrocyclic compounds
11/02/2006	EP1716152A2 Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders
11/02/2006	EP1716151A1 Compositions useful as inhibitors of protein kinases
11/02/2006	EP1716150A2 Substituted heterocyclic compounds and methods of use
11/02/2006	EP1716149A2 Method for the production of crystalline (6rs)-n(5)-formyl-5,6,7,8-tetrahydrofolic acid
11/02/2006	EP1716148A2 Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
11/02/2006	EP1716147A1 Diaza-spiropiperidine derivatives as inhibitors of glycine transporter 1 and glycine transporter 2
11/02/2006	EP1716146A1 Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof
11/02/2006	EP1716145A1 Dihydrotetrabenazines and pharmaceutical compositions containing them
11/02/2006	EP1716143A1 Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
11/02/2006	EP1716142A2 Oxazole derivatives, preparation and therapeutic use therof
11/02/2006	EP1716141A1 Benzopyran derivatives, method of production and use thereof
11/02/2006	EP1716137A1 Substituted quinoline compounds
11/02/2006	EP1716136A1 Pyridine benzimidazole sulfoxides of high purity
11/02/2006	EP1716135A1 Piperidinylcarbonyl-pyrrolidines and their use as melanocortin agonists
11/02/2006	EP1716134A1 Amino heterocyclic modulators of chemokine receptor activity
11/02/2006	EP1716133A1 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors
11/02/2006	EP1716132A2 Spiro-benzodioxoles and their use as cb1 antagonists
11/02/2006	EP1716130A1 Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists
11/02/2006	EP1716129A1 Piperazine derivatives which exhibit acivity as serotonin and noradrenaline re-upatke inhibitors
11/02/2006	EP1716127A2 Guanidine compounds, and use thereof as binding partners for 5-ht5 receptors
11/02/2006	EP1716126A1 Morpholine derivatives as norepinephrine reuptake inhibitors
11/02/2006	EP1716125A1 Tetrazole compounds and their use as metabotropic glutamate receptor antagonits
11/02/2006	EP1716123A1 Pyridazinone derivatives and their use as pde4 inhibitors
11/02/2006	EP1716121A1 Polymorph of birb 796, a p38map kinase inhibitor
11/02/2006	EP1716119A1 Analogs of benzoquinone-containing ansamycins for the treatment of cancer
11/02/2006	EP1716118A1 Tetrahydrobenzo[d]azepin-2- one derivatives and the use thereof for treating cardiovascular diseases
11/02/2006	EP1716117A1 Ionic uv-a sunscreens and compositions containing them
11/02/2006	EP1716116A1 Alpha-(trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents
11/02/2006	EP1716113A1 Ep2- receptor agonists
11/02/2006	EP1716110A1 Androgen receptor modulators
11/02/2006	EP1716101A1 Aromatic a-ring derivatives of tetracycline compounds
11/02/2006	EP1715971A1 Functionalized colloidal metal compositions and methods
11/02/2006	EP1715921A2 Tetrahydroindolone derivatives for treatment of neurological conditions
11/02/2006	EP1715920A1 Cathepsin cysteine protease inhibitors
11/02/2006	EP1715896A1 Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in combination therapies for the treatment of cancer
11/02/2006	EP1715894A2 Stable gabapentin compositions
11/02/2006	EP1715890A1 Ctgf as target for the therapy of diabetic nephropathy
11/02/2006	EP1715883A1 18-membered nitrobenzyl-substituted and aminobenzyl-substituted cyclohexadepsipeptides for controlling endoparasites, and method for the production thereof
11/02/2006	EP1715878A2 Use of an extract of pueraria tuberosa for the treatment of diabetes type 2
11/02/2006	EP1715877A1 Compositions and methods for reducing cholesterol comprising guggul and beta-glucan and/or plant sterols
11/02/2006	EP1715873A1 Nucleoside phosphonate derivatives useful in the treatment of hiv infections
11/02/2006	EP1715872A1 Improved therapy using a combination of raloxifene and alendronate

1 ... 4026 4027 4028 4029 4030 4031 4032 4033 4034 4035 4036 4037 4038 4039 4040 4041 4042 4043 4044 4045 4046 ... 7860